Skip To Main Content
Upreti VV on Muck Rack

Upreti VV

Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Upreti

Contact Upreti, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Best Practices & Considerations for Clinical Pharmacology & Pharmacometric Aspects for Optimal Development of CAR-T & TCR-T Cell Therapies: An Industry Perspective - PubMed

|
By Yang TY, Upreti VV, Shastri PN, Liao MZ
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (555) Issue with article?

Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight

|
By Upreti VV, Barrett YC, Boyd RA, LaCreta FP
| AHA/ASA Journals
Clinical Perspective What Is New? Apixaban is efficacious and safe across the spectrum of weight, including in low- (≤60 kg) and high-weight patients (>120 kg). The superiority on efficacy and safety outcomes of apixaban compared with warfarin persists across weight groups, with even greater reductions in major bleeding in patients with atrial fibrillation with low to normal weight as compared with high weight. What Are the Clinical Implications?
Open in Who Shared Issue with article?
See all 2 articles